[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577540":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":25,"responsibleParty":39,"collaborators":10,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":43,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":10,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":63,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with endometrial cancer eligible for fertility-sparing treatment",null,"Patients diagnosed with endometrial cancer who meet the criteria for inclusion in a fertility-sparing treatment pathway and for whom molecular classification data is available.",[13],"Other: Observation only",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Observation only","Only observation following standard of care (histological diagnosis, molecular classification, progestine therapy)",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Filippo Ferrari, MD","CONTACT","3803933116","filippo.ferrari@istitutotumori.mi.it",[26],{"facility":27,"status":10,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":10},"Fondazione IRCCS Istituto Nazionale dei Tumori di Milano","Milan","Michigan","20133","Italy","IT",{"type":34,"coordinates":35},"Point",[36,37],12.59836,42.78235,{"lat":37,"lon":36},{"type":40,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100577540","prognostic-role-of-molecular-classification-in-fertility-sparing-treatment-of-endometrial-cancer-100577540",false,"NCT06799624","Prognostic Role of molEcular classiFication in Fertility-sparing treAtment of Endometrial canCEr","Prognostic Role of molEcular classiFication in Fertility-sparing treAtment of Endometrial canCEr: PREFACE Study","PREFACE","Inclusion Criteria:\n\n1. Patients aged 18-45 years with a hysteroscopic confirmed diagnosis of endometrial cancer (FIGO stage IA without myometrial invasion, grade 1 or grade 2, endometrioid histology).\n2. Patients desiring fertility preservation\n3. Molecular classification of the tumor using next-generation sequencing (NGS) or Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE).\n4. Adequate pre-treatment imaging (MRI or transvaginal ultrasound) confirming no evidence of myometrial invasion or extrauterine spread.\n\nExclusion Criteria:\n\n1. Patients with atypical endometrial hyperplasia or intraepithelial neoplasia\n2. Individuals with tumor samples of insufficient quantity or inadequate quality were not included in the analysis\n3. Non-endometrioid histology.\n4. Patients with a history of prior uterine malignancy or current synchronous malignancies.\n5. Medical contraindications to hormonal therapy","FEMALE","18 Years","50 Years",{"count":53,"type":54},100,"ESTIMATED","OBSERVATIONAL","Endometrial cancer, the most common gynecologic malignancy in high-income countries, is increasing among reproductive-age women. While hysterectomy prevents pregnancy, hormonal therapies offer fertility-sparing options for select early-stage cases, with \\~80% achieving complete response (CR). Molecular classifications (POLEmut, p53abn, MMRd\u002FMSI-H, NSMP) reveal subtype-specific prognostic differences, with NSMP showing higher CR rates and lower recurrence, while p53abn and MMRd\u002FMSI-H fare worse. Recent studies emphasize molecular profiling's potential to guide personalized fertility-sparing treatments. This study explores the prognostic role of these classifications in treatment outcomes.",[58],"Uterine Cancer",[60,61,62],"uterine cancer","fertility-sparing","molecular classification","NOT_YET_RECRUITING","2025-12-16",{"date":66,"type":67},"2025-12-23","ACTUAL",{"date":69,"type":54},"2026-01-01",{"date":71,"type":54},"2028-01-31",{"name":5,"class":6},1]